Novaccess Global is at the forefront of developing innovative immunotherapeutic solutions, particularly through its patented technology known as TLR-AD1. This approach aims to enhance the body’s immune response against cancer by utilizing a combination of dendritic cell-based therapies and Toll-like receptor (TLR) adjuvants. Specifically designed for treating glioblastoma, the most prevalent form of brain tumor, TLR-AD1 seeks to empower patients' immune cells to recognize and eliminate cancer cells more effectively. The therapy is currently in the Investigational New Drug (IND) filing stage, with plans to initiate human clinical trials pending regulatory approval.

In addition to its immunotherapy initiatives, Novaccess Global is leveraging advanced technologies such as artificial intelligence and blockchain to revolutionize cancer and neurological diagnostics. By employing state-of-the-art bio-sensing technologies, the company aims to significantly enhance the speed and accuracy of cancer detection and treatment implementation. This cutting-edge approach not only focuses on personalized patient care but also strives to improve the overall efficacy of cancer therapies, marking a significant advancement in the field of precision medicine.

United States

NovAccess Global is a biomedical company accelerating and investing in novel cancer diagnostics and therapeutics.

Novaccess Global

Company Details